Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
- Advertisement -
Recover your password.
A password will be e-mailed to you.
PARIS–(BUSINESS WIRE)–Regulatory News:
- Advertisement -
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the Company will participate and present LUMEVOQ® data at the following upcoming medical conferences taking place in the first half of 2023:
North American Neuro Ophthalmology Society (NANOS) 49th Annual Meeting
March 11 – 16, 2023 – Orlando, USA
Presentation: “Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs”
Presentation: “Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4 LHON patients: the RESTORE study”
Presentation: “Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in m.11778G>A MT-ND4 Leber hereditary optic neuropathy patients”
Presentation: “Bilateral improvement after unilateral AAV2 gene therapy for LHON: update and bilateral ocular post-mortem analyses”
The American Academy of Neurology (AAN) Annual Meeting
April 22 – 27, 2023 – Boston, USA
Presentation: “Indirect comparison of lenadogene nolparvovec gene therapy versus natural history in m.11778G>A MT-ND4 Leber hereditary optic neuropathy patients”
Presentation: “Long-term follow-up of m.11778G>A MT-ND4-LHON patients treated with lenadogene nolparvovec ocular gene therapy: the RESTORE study”
The Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting
April 23 – 27, 2023 – New Orleans, USA
Presentation: “Use of lenadogene nolparvovec gene therapy for Leber hereditary optic neuropathy in early access programs”
Presentation: “Treatment with lenadogene nolparvovec gene therapy results in sustained visual improvement in m.11778G>A MT-ND4-LHON patients: the RESTORE study”
Presentation: “Histopathological and molecular characterization in ocular post-mortem analyses following AAV2 gene therapy for LHON”
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is an investigational compound and has not been registered in any country at this stage; a marketing authorization application is currently under review by the EMA for the treatment of Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease affecting primarily teens and young adults that leads to irreversible blindness. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Contacts
GenSight Biologics
Corporate Communications Director
Clothilde Caillet
ccaillet@gensight-biologics.com
LifeSci Advisors
Investor Relations
Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0)76 735 01 31
RooneyPartners
Media Relations
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646-770-8858
Orpheon Finance
Retail Investors
James Palmer
j.palmer@orpheonfinance.com
+33 (0)7 60 92 77 74
Get real time updates directly on you device, subscribe now.
- Advertisement -